Latest Derivatives News

Fletcher Building unveiled a comprehensive strategic review and FY25 outlook at its Investor Day, highlighting a focus on manufacturing and distribution alongside significant restructuring costs. The company targets a leaner operation with disciplined capital management and a net debt goal of NZD 400m to 900m.

INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.

Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.

Commonwealth Bank of Australia announces a fully franked quarterly dividend of AUD 1.1581 per security on its PERLS XV capital notes, payable in September 2025.

Commonwealth Bank of Australia announces a fully franked quarterly distribution of AUD 1.1405 per security on its PERLS XIV capital note, payable mid-September 2025.

Commonwealth Bank of Australia announces a fully franked quarterly distribution of AUD 1.1405 per security on its PERLS XIII capital note, payable mid-September 2025.

Commonwealth Bank of Australia announces a fully franked quarterly dividend of AUD 1.1846 per PERLS XII security, payable in September 2025, reflecting steady income for investors.

Lithium Universe Limited has acquired exclusive global rights to a pioneering microwave-based technology for recycling photovoltaic solar panels, offering a strategic pivot while awaiting lithium market recovery.

INOVIQ Limited has announced a breakthrough in its cancer treatment program, with its CAR-exosome therapy killing 88% of triple negative breast and lung cancer cells in laboratory studies. This innovation could pave the way for faster, safer, and more accessible cancer therapies.

RLF AgTech has secured exclusive rights to distribute AXIOMA Biologicals’ advanced biostimulant products across Australia, China, and Asia, marking a strategic move into the biologicals market segment.

AMP Limited has announced a quarterly distribution of AUD 1.9069 per AMP Capital Notes 2 security, payable in September 2025, reflecting a total annualised yield of 7.57%.

Peninsula Energy reports progress on its Lance Project’s Central Processing Plant and announces the termination of three sales contracts as part of a strategic reset plan, while engaging in funding discussions to support completion.